“Everyone has the possibility of experiencing a drug gene interactions and we are still learning the best way to identify these individuals and develop strategies for personalized treatment,” says first author Dr. Amy Pasternak.
A key focus of Precision Health, drug gene interactions occur when a patient’s genome impacts how their body processes a drug.
Lead author Antoinette Coe, PharmD, PhD, Assistant Professor of Clinical Pharmacy
Most older adults take multiple drugs but 80% haven’t had a medication review to check safety and potential savings, and 83% them don’t realize it may be covered by insurance.
Many people don’t realize that the trillions of bacteria, viruses, and fungi residing within the gastrointestinal tract—collectively called the gut microbiome—are connected to overall health, and specifically to cancer.
Discovering and engineering nanobodies with properties suitable for treating human diseases ranging from cancer to COVID-19 is a time-consuming, laborious process.
The goal of Dr. Luzum’s research is to use precision medicine, particularly genetics, to improve cardiovascular outcomes from medications. Adverse cardiac outcomes from drugs used to treat COVID-19 have recently been a major concern.
The COVID-19 pandemic continues to impact global health and safety. Numerous drugs are under expedited investigations, without well-established safety or efficacy data.
Patients who received single intravenous dose of tocilizumab were also more likely to leave the hospital or be off ventilator within a month, despite double the risk of additional infection